The delegation, supported by the National Development Council’s Startup Island TAIWAN and the Development Center for Biotechnology, showcased a diverse portfolio ranging from AI-powered reproductive health to next-generation antibody therapeutics. During the four-day event, these companies moved beyond initial introductions, engaging in concrete discussions regarding licensing, co-development, and manufacturing scale-up.
In section Releases
Taiwanese Biotech Startups Secure Over 100 Deals at BIO 2026
Six Taiwanese biomedical firms leveraged the BIO International Convention in San Diego to push their innovations onto the global stage, securing more than 100 high-level meetings with pharmaceutical giants and international investors to accelerate the commercialization of their precision medicine and organoid technologies.
AB DigiHealth and CancerFree Biotech utilized the summit to advance distribution talks for their respective reproductive health and organoid platforms. Meanwhile, PlasmonicTron, Taiwan Universe BioMedicine, and Precisemab Biotech focused on connecting with Contract Research Organizations and potential clinical collaborators. Precisemab’s Universal Antibody Lock™ platform, in particular, drew significant interest from partners looking to enhance the precision of monoclonal and bispecific antibody treatments. This surge in activity underscores the growing technical maturity of Taiwan’s biotech sector and its increasing integration into the global pharmaceutical supply chain.
Comments (0)
No comments yet. Be the first!